


Epidemiological study of *Trichosporon asahii* infections over the past 23 years

cambridge.org/hyg

Haitao Li^{1,*}, Meihong Guo^{1,*}, Congmin Wang^{1,*}, Yibo Li², Anne Marie Fernandez³, Thomas N. Ferraro⁴, Rongya Yang¹ and Yong Chen³ 

Review

*Co-first authors.

Cite this article: Li H, Guo M, Wang C, Li Y, Fernandez AM, Ferraro TN, Yang R, Chen Y (2020). Epidemiological study of *Trichosporon asahii* infections over the past 23 years. *Epidemiology and Infection* **148**, e169, 1–8. <https://doi.org/10.1017/S0950268820001624>

Received: 17 January 2020

Revised: 12 July 2020

Accepted: 13 July 2020

Key words:

Clinical characterisation; fungi infection; therapeutic prognosis; *Trichosporon asahii*

Authors for correspondence:

Rongya Yang, E-mail: rongyang@gmail.com;

Yong Chen, E-mail: chenyong@rowan.edu

¹Department of Dermatology, The Seventh Medical Center of PLA General Hospital, Dongcheng, 100700, Beijing, China; ²Department of Biological Sciences, Center for Systems Biology, the University of Texas at Dallas, Richardson, TX 75080, USA; ³Department of Molecular and Cellular Biosciences, Rowan University, Glassboro, NJ 08028, USA and ⁴Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA

Abstract

Trichosporon is a yeast-like basidiomycete, a conditional pathogenic fungus that is rare in the clinic but often causes fatal infections in immunocompromised individuals. *Trichosporon asahii* is the most common pathogenic fungus in this genus and the occurrence of infections has dramatically increased in recent years. Here, we report a systematic literature review detailing 140 cases of *T. asahii* infection reported during the past 23 years. Statistical analysis shows that *T. asahii* infections were most frequently reported within immunodeficient or immunocompromised patients commonly with blood diseases. Antibiotic use, invasive medical equipment and chemotherapy were the leading risk factors for acquiring infection. *In vitro* susceptibility, clinical information and prognosis analysis showed that voriconazole is the primary drug of choice in the treatment of *T. asahii* infection. Combination treatment with voriconazole and amphotericin B did not show superiority over either drug alone. Finally, we found that the types of infections prevalent in China are significantly different from those in other countries. These results provide detailed information and relevant clinical treatment strategies for the diagnosis and treatment of *T. asahii* infection.

Introduction

Over the past 30 years, the incidence of fungal infection has increased dramatically in patients with cancer, deep burns, organ transplants and those under treatment with hormones and immunosuppressive agents, becoming one of the main causes of death in these individuals. In addition to common fungal infections such as candidiasis and aspergillosis, infections caused by non-candida yeast such as trichosporonosis are increasing in immunosuppressed, immunocompromised and immunodeficient individuals with severe conditions and high mortality rates [1–4]. *Trichosporon* is a yeast-like basidiomycete. It is ubiquitous in nature meaning it is present in soil, water, plants, mammals, birds, etc. and is also present among the human body's natural flora; however, it can become pathogenic to the humans in certain cases [5–8]. Hermann Beigel first proposed the concept of *Trichosporon* in 1865 and observed that it can cause hair infection. The classification and naming of *Trichosporon* has then changed multiple times over the years. Initially, all *Trichosporon* spp. were classified as *Trichosporon beigeli*, and it was thought that the strain mainly causes infection in superficial hair, and rarely causes deep-seated infection [6]. However, subsequent research showed that *T. beigeli* has great morphologic variation, as well as physiological and biochemical variance [9]. In 1992, Gueho *et al.* revised the taxonomy of 20 species of *Trichosporon*, including six pathogens: *Trichosporon asahii*, *T. asteroides*, *T. cutaneum*, *T. inkin*, *T. mucoides* and *T. ovoides* [6, 10–12]. In 1994 and 1995, Sugita *et al.* reviewed the genus *Trichosporon* and proposed a new classification that included 17 different species of *Trichosporon* and five varieties [13]. By 2002, the number of *Trichosporon* species had increased to 25, of which eight were associated with human infections, including two new species, *T. domesticum* and *T. montevidense* [14]. Presently, 50 *Trichosporon* species are recognised, of which 16 are known to be pathogenic [15–19].

Current research indicates that risk factors for *Trichosporon* infection include neutropaenia (an abnormally low amount of neutrophils), organ transplantation, diabetes, end-stage renal disease, HIV infection and use of immunosuppressive agents and invasive medical equipment [5, 6, 20–27]. *Trichosporonosis* is associated with a variety of infection types, including superficial skin and hair infections, summer-type hypersensitivity pneumonitis (SHP), chronic pneumonia, meningitis, endocarditis, disseminated infections and fungaemia [28–41]. *Trichosporon* infections are also often misdiagnosed as other types of fungal infections [42], and have proven difficult to treat. Before 2000, physicians recommended amphotericin B for treatment of *Trichosporon* infections; however, usage of this drug has been reported

© The Author(s), 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

CAMBRIDGE
UNIVERSITY PRESS

to be ineffective [43]. The combination of amphotericin B and flucytosine was also suggested for treatment [37, 44, 45], but no studies are published that compare effectiveness between combined and individual antifungal drug treatment. When azole pharmaceuticals appeared on the market (especially voriconazole), most *in vitro* susceptibility testing showed that they were superior to amphotericin B for treating trichosporosis [46–48]; however, the *in vitro* effects of antifungal drugs are not fully representative of their therapeutic effectiveness in humans. The guidelines developed by ESCMID/ECMM in 2014 recommend voriconazole for the treatment of trichosporosis, although it is noted that the development of this guide relies mainly on *in vitro* susceptibility testing results, animal model test results and a few case reports [49].

Almost all cases of *Trichosporon* infection reported before 1994 were named *T. beigelii*. In contrast, isolates of *Trichosporon* spp. reported in the past 20 years are of various types, and numerous species of *Trichosporon* are known to exhibit different pathogenic characteristics. For example, *T. asteroides* and *T. cutaneum* are the main pathogenic species known to cause superficial skin infections [6]. On the other hand, *T. asahii* is the most prominent clinical pathogen in the genus. *T. asahii* causes more than half of the infections of the genus [50], and the mortality caused by deep invasive infections is greater than 70%. In 1992, Gueho *et al.* [6] proposed another classification of *Trichosporon* spp., and confirmed that *T. asahii* was the main pathogen causing deep trichosporosis.

The incidence of *T. asahii* infection has increased significantly in the past 20 years [1, 3]. It is commonly found in immunodeficient and immunocompromised patients, and individuals with blood diseases [23, 51, 52]. A few studies also reported *T. asahii* infection in healthy individuals [21, 22]. In addition, different species of *Trichosporon* possess different drug sensitivities. For example, amphotericin B has a higher minimum inhibitory concentration (MIC) against *T. asahii*, *T. faecale* and *T. coremiiforme*, while *T. inkin*, *T. ovoides*, *T. japonicum*, *T. domesticum*, *T. montevidense* and *T. cutaneum* have lower MICs [46, 53–56]. Therefore, it is important to accurately analyse the epidemiological characteristics of different species of *Trichosporon* so the susceptibility and risk factors of infection can be obtained. This information can then enhance patient diagnosis, treatment, medication and outcome prediction.

Accurate epidemiological analysis of *Trichosporon* infections, especially *T. asahii*, can highlight susceptibility to infection and improve patient diagnosis, treatment and prognosis. Although there is some literature reviewing *Trichosporon* disease [57–59], a comprehensive analysis of epidemiological characteristics, clinical treatment and prognosis of *T. asahii* infection has not been published. Here we systematically analysed the epidemiological characteristics, risk factors, clinical manifestations, diagnosis, treatment, medication and prognosis of *T. asahii* infections reported in the English literature from 1996 to 2019 and in Chinese literature from 2009 to 2019. We then compared the infections in China with those in other countries to determine significant differences in divergent clinical categories.

Materials and methods

Literature collection

In order to do a comprehensive analysis of clinical studies regarding *T. asahii* infections, we performed a systematic literature review to identify original cases in both English and Chinese literature. First, we reviewed all references from the PubMed

database by using the keywords *T. asahii*, *trichosporon asahii* and *trichosporonosis*. The search was then limited to studies including human subjects, clinical trials and case reports. A search was also conducted on the Chinese medical database WANFANG (<http://www.wanfangdata.com.cn/index.html>). To standardise analysis, the following patient information was examined for each case: time of onset, study area, demographic data, possible pathogenesis, type of underlying disease, source of specimen, identification method of strain, type and location of infection, treatment and outcome. Published studies with missing case information from any of these categories were excluded. All literature reviewed was published between 1996 and 2019.

Statistical analysis of epidemiological data

For each category, the distribution of data was analysed by using a descriptive statistical analysis. To understand the different causal factors and therapy results between 51 Chinese cases and 89 cases from other countries, we compared each cohort with respect to the patient information. A Fisher's exact test was used to compare the effectiveness of the three antifungal drug groups (amphotericin B; triazoles; amphotericin B plus triazoles), where $P < 0.05$ was considered statistically significant.

Results

Patient population

Systematic literature review yielded a total of 140 cases of *T. asahii* infection, including 51 cases in Chinese literature and 89 in English literature reported from 1996 to 2019. These cases were distributed throughout Asia, Europe, North and South America and Africa, in which Asia had the largest proportion (108/140, 77.1%). Cases reported from China, Japan and India represented 65.7% of the total. Among other countries and regions, 10 cases were reported from the United States (Fig. 1a). The number of cases in Asia dramatically increased from 2006 to 2015, but only 16 cases were observed in other years (Fig. 1b).

Of the 140 patients with *T. asahii* infection, 83 were male (83/140, 59.3%), 47 were female (47/140, 33.6%) and the gender of remaining 10 patients was not reported (eight were newborn premature infants), achieving a ~1.77-fold ratio of males to females. The age of onset ranged from 0 to 92 years old, where the group of individuals over 65 years old represented the largest proportion (48/140, 34.3%). For cases from Asia, the older individual groups have higher proportions of *T. asahii* infection, which is also consistent with observations from Europe and the Americas (Fig. 1c).

Risk factors for *T. asahii* infection

Previous studies found divergent risk factors related to trichosporosis including antibiotic usage, invasive medical equipment, intensive care unit (ICU) hospitalisation and others [60, 61]. Among the 140 patients with *T. asahii* infection, we also found that antibiotic and invasive medical equipment users were the two major groups with proportions of 46.4% (65/140) and 44.3% (62/140), respectively (Fig. 2a). Overall, the use of broad-spectrum antibiotics, the use of invasive medical devices, neutropenia and ICU hospitalisation remain the four greatest risk factors for *T. asahii* infection. Our results proved to be consistent with previous studies. For example, Kontoyannis *et al.* [61] analysed 17 patients with trichosporosis and a history of oncology




Fig. 2. Proportions of 140 cases on risk factors (a), infected tissues (b), test samples (c) and testing methods (d).

Table 1. Statistical summary of 22 breakthrough IFI with prior antifungal treatment/prophylaxis

| Prophylactic antifungal drugs | No. (%) | Citations (PMID) |
|---|----------|--|
| Echinocandin | 5 (22.7) | 24383917, 23419599, 25328390, 17882360 |
| Amphotericin B | 6 (27.3) | 26351595, 18362402, 12087540, 16964817, 16217998 |
| Fluconazole | 3 (13.6) | 22370746, 20436525, 11337182 |
| Itraconazole | 2 (9.1) | 17322000, 16838224 |
| Posaconazole | 1 (4.6) | 17690928 |
| Fluconazole + micafungin | 1 (4.6) | 15231763 |
| Fluconazole + amphotericin B | 2 (9.1) | 25383317, 11477533 |
| Fluconazole + itraconazole + amphotericin B | 1 (4.6) | 23970618 |
| Unknown | 1 (4.6) | 18356615 |

obtained from blood (33.6%), 39 were diagnosed from a urine specimen (27.9%) and 27 were diagnosed from a sputum specimen (19.3%). A complete description of samples used for testing can be found in Figure 2c. Of the 140 *T. asahii* cases, 135 cases

Table 2. The underlying disease types of 140 patients^a with *T. asahii* infection

| Types of underlying disease | No. (%) | Types of underlying disease | No. (%) |
|-----------------------------|-----------|-----------------------------|---------|
| Blood disease | 39 (27.9) | Malignant tumour | 4 (2.9) |
| Diabetes | 19 (13.6) | Fracture | 4 (2.9) |
| Lung disease | 17 (12.1) | AIDS | 3 (2.1) |
| Other | 14 (10) | Organ transplantation | 3 (2.1) |
| Premature infants | 10 (7.1) | Chronic gastritis | 3 (2.1) |
| After surgery | 7 (5) | Hypothyroidism | 2 (1.4) |
| Chronic renal insufficiency | 6 (4.3) | Rheumatoid arthritis | 2 (1.4) |
| Summer allergic pneumonia | 4 (2.9) | Diabetic nephropathy | 1 (0.7) |

^aSome patients have more than one underlying disease.

(96.4%) described the method for identifying *T. asahii*. Morphological methods combined with biochemical methods were used most commonly (96/135, 71.1%). The antigen inhalation test was the identification method used for the five patients with SHP (Fig. 2d). Among the 135 cases, 128 patients (128/135 94.8%) were tested by using morphological methods (API 20C AUX yeast identification system, ID 32C yeast identification system, Vitek automatic microbial identification system).

Table 3. Clinical illnesses in patients with *T. asahii* infection

| Type of infection | No. (%) | Type of infection | No. (%) |
|------------------------|-----------|---------------------------|---------|
| Urinary infection | 35 (25) | Glossitis | 1 (0.7) |
| Fungaemia | 33 (23.6) | Conjunctivitis | 1 (0.7) |
| Disseminated infection | 20 (15.7) | Discitis | 1 (0.7) |
| Lung infection | 15 (10.7) | Infective endocarditis | 1 (0.7) |
| Skin infections | 8 (5.7) | Black hairy knot disease | 1 (0.7) |
| Chronic pneumonia | 7 (5) | Lymphadenitis | 1 (0.7) |
| Other | 4 (2.9) | Endophthalmitis | 1 (0.7) |
| Peritonitis | 3 (2.1) | Brain abscess | 1 (0.7) |
| Meningoencephalitis | 2 (1.4) | Synovitis | 1 (0.7) |
| Esophagitis | 2 (1.4) | Summer allergic pneumonia | 1 (0.7) |

Table 4. Drug effectiveness by *in vitro* drug sensitivity test in 140 patients^a with *T. asahii* infection

| Drug | 1996–2005 | 2006–2019 |
|----------------|------------|-------------|
| | No. (%) | No. (%) |
| Amphotericin B | 1 (10) | 24 (21.8) |
| Voriconazole | 4 (40) | 41 (37.3) |
| Itraconazole | 3 (30) | 19 (17.3) |
| Miconazole | 0 (0) | 1 (0.9) |
| Ketoconazole | 1 (10) | 0 (0) |
| Fluconazole | 1 (10) | 25 (22.7) |
| Total | 10 (100.0) | 110 (100.0) |

^aSome patients were sensitive to more than one drug.

Biochemical techniques were used in 119 cases (119/135, 88.1%) and 24 cases (24/135, 18.4%) used a genetic method (LSU, D1/D2, ITS region nucleic acid sequence determination).

In vitro susceptibility test

Of the 140 patients with *T. asahii* infection, 91 had an *in vitro* susceptibility test, consisting of 10 cases from 1996 to 2005 and 81 cases from 2006 to 2019. Among the 10 patients who had an *in vitro* susceptibility test from 1996 to 2005, four of them were sensitive to the antifungal drug voriconazole. Of the 81 patients who had *in vitro* susceptibility test between 2006 and 2015, 41 were sensitive to voriconazole, accounting for 37.3% of all patients (Table 4). Among *in vitro* susceptibility test methods, the M27-A2, M27-A3 and E-test methods were used widely on *T. asahii* infection patients.

Drug selection

Regarding treatment and medication options for *T. asahii* infection, the ESCMID/ECMM guidelines recommended the use of voriconazole for the treatment of trichosporosis in 2014. The guidelines were based on the results of *in vitro* susceptibility testing, animal model testing and supporting evidence from a few case reports of Trichosporon infection [49]. However, more than 50 species of Trichosporon have been identified currently

(a)

| | | | Triazoles | Amphotericin B combined with triazoles |
|--|-------------|----|-----------|--|
| Amphotericin B | Effective | 24 | $p=0.015$ | $p=0.353$ |
| | Ineffective | 10 | | |
| Triazoles | Effective | 43 | $p=0.25$ | $p=0.25$ |
| | Ineffective | 15 | | |
| Amphotericin B combined with triazoles | Effective | 11 | $p=0.25$ | $p=0.25$ |
| | Ineffective | 8 | | |




Fig. 3. Statistical analysis of drug susceptibility testing and clinical outcome. (a) *In vitro* drug susceptibility testing of triazoles and amphotericin B. The *P*-value was calculated by using Fisher's exact test. (b) Mortality rate of different infection types.

and different species of Trichosporon exhibit different levels of sensitivity to drugs. For example, the MIC of amphotericin B for *T. asahii*, *T. faecale* and *T. coremiiforme* was relatively higher, than that for *T. inkin*, *T. ovoides*, *T. japonicum*, *T. domesticum*, *T. montevidense* and *T. cutaneum* [46, 53–55]. Therefore, this guideline has a limited reference value for the usage of voriconazole in treatment of *T. asahii* infection.




Fig. 4. Comparative analysis of 51 Chinese patients and 89 patients in other countries. Comparative distributions were shown for (a) infection types, (b) inducing factors, (c) drug sensitivity and (d) mortality.

Of the 140 patients with *T. asahii* infections, the treatment strategies were complex (Fig. 3a). The efficiency of single-drug therapy of amphotericin B was 70.6%, whereas the efficiency of triazole in antifungal therapy was 74.1%. The difference between the two groups was statistically significant ($P = 0.015$). However, the efficacy of a combined dosage of amphotericin B and triazole was reduced to 57.9%. There was no significant difference between the combination group and the single drug group ($P > 0.05$), but the efficacy of triazole in anti-*T. asahii* infection was better than amphotericin B ($P < 0.05$).

Outcomes

Previous studies have shown that the mortality rate of *Trichosporon* infection can range from 53% to 80% [48, 61, 63, 64], but these studies only examined the mortality rate, and did not analyse the specific cause of death. They failed to answer questions such as whether the patient died from *Trichosporon* infection or other underlying diseases or if the main cause of death was due to complications resulting from the underlying disease. To clarify the mortality rate due to *T. asahii* infection, we excluded patients who died from underlying diseases and other causes of death. Only patients with death caused by *T. asahii* infection were considered. Of the 140 patients with *T. asahii* infection, the overall mortality rate of 140 patients was 30.0%, and the mortality rate caused by *T. asahii* infection was 13.6%. Furthermore, mortality was different in patients with varying infection types of *T. asahii*. Fungaemia was associated with the highest mortality rate, 51.5%, including 30.3% caused by *T. asahii* infection. This was followed by

disseminated infection at 40.0%. Of note, 35% of deaths were caused solely by *T. asahii* infection (Fig. 3b).

Comparative analysis of cases in China and other countries

Since there were a large number of patients reported in China, we also statistically compared the characteristics of Chinese patients with those of other countries. We found that fungaemia and pulmonary infection in Chinese patients was higher than in other countries (>3-fold). On the other hand, the number of patients with urinary tract infections in other countries was greater compared to China (>3-fold) (Fig. 4a). For risk factors, we confirmed that antibiotic treatment and invasive medical device users were the most common in both cohorts. However, the number of patients with risk factors such as chemotherapy, neutrophil reduction and bacterial infection was greater in other countries compared to China (>3-fold) (Fig. 4b).

For the methods of identification and diagnosis, both China and other countries used standard morphological and biochemical methods (>50%). The results of the *in vitro* drug sensitivity test were also very similar. Comparisons of clinical drug usage showed no difference, and both groups preferred triazoles and amphotericin B (Fig. 4c). However, the overall mortality rate reported in Chinese patients was lower (21.6%) than that of other countries (34.8%) (Fig. 4d).

Discussion

This study investigated 140 global *T. asahii* infection cases reported within the past 23 years. For statistical and comparative

analysis, we used critical criteria to select both English and Chinese reports of *T. asahii* infections. We found that the number of *T. asahii* infections showed a dramatic increase from 2006 to 2015 (107 cases) in Asia. We also found that the patients in this study mainly used triazole antifungal drugs or amphotericin B alone, or the combination of triazoles and amphotericin B. The results showed that the antifungal effect of triazoles, such as voriconazole, fluconazole and itraconazole was the most effective in the treatment of *T. asahii* infection. This is consistent with the guidelines developed by ESCMID/ECMM in 2014. Furthermore, we found that the combined usage of amphotericin B and triazole was less effective than individual triazole drug usage. Therefore, our results suggest that the first recommended drug for the treatment of *T. asahii* infection should be a triazole. The statistical ranking of drug sensitivities based on *in vitro* susceptibility test (Table 4) suggests that voriconazole would be the first choice for treatment, followed by fluconazole, amphotericin B and itraconazole.

Since many of *T. asahii* infections were reported in Chinese, we further collected and investigated 51 Chinese cases. Through the comparison of cases between China and other countries, we found that although they are very similar for a majority of the criteria studied, there are still many differences. In particular, fungaemia and pulmonary infections were greater in Chinese patients, but urinary tract infections had a lower frequency in Chinese patients than in cases from other countries. Due to the strict inclusion criteria in this study, the actual incidence of *T. asahii* infections in the world is greater than 140 cases. Therefore, a more accurate epidemiological analysis of *T. asahii* infection requires collaboration with researchers from all over the world. We found that many types of clinical information, such as the infection process and the source of their pathogens, are missing. But this information could be valuable for understanding the infection process and mechanism of *T. asahii*. For example, a recent time series study of breakthrough IFIs [62] defined different clinic trail patterns of breakthrough IFI. A similar analysis can be performed for *T. asahii* infections if detailed and time series clinic records can be amassed. Meanwhile, acting as a reference for the clinical drug selection to treat *T. asahii* infection, our study can be improved by precisely controlling confounding factors including weight, vital organ function, etc. that were inaccessible now. Therefore, specific information such as the appropriate therapeutic dose, maintenance dose and duration of treatment remain to be determined.

Financial support. This project was supported partly by the National Natural Science Foundation of China (Grant Numbers 81472892 and 81571972)

Conflict of interest. The authors declare no competing financial interests.

Data availability. The authors confirm that the data supporting the findings of this study are available within the article.

References

- Gross JW and Kan VL (2008) *Trichosporon asahii* infection in an advanced AIDS patient and literature review. *AIDS (London, England)* **22**, 793–795.
- Biasoli MS *et al.* (2008) Systemic infection caused by *Trichosporon asahii* in a patient with liver transplant. *Medical Mycology* **46**, 719–723.
- Bayramoglu G *et al.* (2008) Breakthrough *Trichosporon asahii* fungemia in neutropenic patient with acute leukemia while receiving caspofungin. *Infection* **36**, 68–70.
- Izumi K, Hisata Y and Hazama S (2009) A rare case of infective endocarditis complicated by *Trichosporon asahii* fungemia treated by surgery. *Annals of Thoracic and Cardiovascular Surgery* **15**, 350–353.
- Haupt HM *et al.* (1983) Colonization and infection with *Trichosporon* species in the immunosuppressed host. *The Journal of Infectious Diseases* **147**, 199–203.
- Gueho E *et al.* (1994) *Trichosporon* on humans: a practical account. *Mycoses* **37**, 3–10.
- Sugita T *et al.* (2000) Isolation of *Trichosporon asahii* from environmental materials. *Medical Mycology* **38**, 27–30.
- Candel FJ *et al.* (2019) Update in infectious diseases 2019. *Revista Espanola de Quimioterapia* **32**, 1–9.
- Lee JW *et al.* (1990) Patterns of morphologic variation among isolates of *Trichosporon beigelii*. *Journal of Clinical Microbiology* **28**, 2823–2827.
- Gueho E *et al.* (1992) Contributions to a revision of the genus *Trichosporon*. *Antonie van Leeuwenhoek* **61**, 289–316.
- Sugita T *et al.* (1999) Identification of medically relevant *Trichosporon* species based on sequences of internal transcribed spacer regions and construction of a database for *Trichosporon* identification. *Journal of Clinical Microbiology* **37**, 1985–1993.
- Sugita T, Nishikawa A and Shinoda T (1998) Rapid detection of species of the opportunistic yeast *Trichosporon* by PCR. *Journal of Clinical Microbiology* **36**, 1458–1460.
- Sugita T *et al.* (1995) Taxonomic position of deep-seated, mucosa-associated, and superficial isolates of *Trichosporon cutaneum* from trichosporonosis patients. *Journal of Clinical Microbiology* **33**, 1368–1370.
- Sugita T *et al.* (2002) Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of *Trichosporon* species. *Journal of Clinical Microbiology* **40**, 1826–1830.
- Fuentefria AM *et al.* (2008) *Trichosporon insectorum* sp. nov., a new anamorphic basidiomycetous killer yeast. *Mycological Research* **112**, 93–99.
- Gujjari P *et al.* (2011) Characterization of oleaginous yeasts revealed two novel species: *Trichosporon cacaoliposimilis* sp. nov. and *Trichosporon oleaginosus* sp. nov. *Mycologia* **103**, 1110–1118.
- Sugita T *et al.* (2005) *Trichosporon* species isolated from guano samples obtained from bat-inhabited caves in Japan. *Applied and Environmental Microbiology* **71**, 7626–7629.
- Taj-Aldeen SJ *et al.* (2009) Molecular identification and susceptibility of *Trichosporon* species isolated from clinical specimens in Qatar: isolation of *Trichosporon dohaense* Taj-Aldeen, Meis & Boekhout sp. nov. *Journal of Clinical Microbiology* **47**, 1791–1799.
- Pagnocca FC *et al.* (2010) Yeasts isolated from a fungus-growing ant nest, including the description of *Trichosporon chiarellii* sp. nov., an anamorphic basidiomycetous yeast. *International Journal of Systematic and Evolutionary Microbiology* **60**, 1454–1459.
- Abdala E *et al.* (2005) *Trichosporon asahii* fatal infection in a non-neutropenic patient after orthotopic liver transplantation. *Transplant Infectious Disease* **7**, 162–165.
- Ebright JR, Fairfax MR and Vazquez JA (2001) *Trichosporon asahii*, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia. *Clinical Infectious Diseases* **33**, E28–E30.
- Karabay O *et al.* (2006) *Trichosporon asahii* fungemia in a patient with non-hematological malignancy. *Japanese Journal of Infectious Diseases* **59**, 129–131.
- Krzossok S *et al.* (2004) *Trichosporon asahii* infection of a dialysis PTFE arteriovenous graft. *Clinical Nephrology* **62**, 66–68.
- Tashiro T *et al.* (1994) Disseminated *Trichosporon beigelii* infection in patients with malignant diseases: immunohistochemical study and review. *European Journal of Clinical Microbiology & Infectious Diseases* **13**, 218–224.
- Barbor PR, Rotimi VO and Fatani H (1995) Paravertebral abscess caused by *Trichosporon capitatum* in a child with acute lymphoblastic leukaemia. *Journal of Infection* **31**, 251–252.
- Wolf DG *et al.* (2001) Multidrug-resistant *Trichosporon asahii* infection of nongranulocytopenic patients in three intensive care units. *Journal of Clinical Microbiology* **39**, 4420–4425.
- Heslop OD *et al.* (2011) Disseminated trichosporonosis in a burn patient: meningitis and cerebral abscess due to *Trichosporon asahii*. *Journal of Clinical Microbiology* **49**, 4405–4408.

28. Nishiura Y et al. (1997) Assignment and serotyping of *Trichosporon* species: the causative agents of summer-type hypersensitivity pneumonitis. *Journal of Medical and Veterinary Mycology* **35**, 45–52.
29. Ogawa H et al. (1998) Seasonal chronic cough with sputum eosinophilia caused by *Trichosporon cutaneum* (*Trichosporon asahii*). *International Archives of Allergy and Immunology* **116**, 162–165.
30. Yoshizawa Y et al. (1999) Chronic hypersensitivity pneumonitis in Japan: a nationwide epidemiologic survey. *Journal of Allergy and Clinical Immunology* **103**, 315–320.
31. Grauer ME et al. (1994) Successful treatment of a *Trichosporon beigelii* septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor. *Infection* **22**, 283–286.
32. Miro O et al. (1994) *Trichosporon beigelii* fungemia and metastatic pneumonia in a trauma patient. *European Journal of Clinical Microbiology & Infectious Diseases* **13**, 604–606.
33. Yoss BS, Sautter RL and Brenker HJ (1997) *Trichosporon beigelii*, a new neonatal pathogen. *The American Journal of Perinatology* **14**, 113–117.
34. Hsu CF et al. (1998) *Trichosporon beigelii* causing oral mucositis and fungemia: report of one case. *Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi* **39**, 191–194.
35. Manzella JP, Berman IJ and Kukrika MD (1982) *Trichosporon beigelii* fungemia and cutaneous dissemination. *Archives of Dermatology* **118**, 343–345.
36. Marin J et al. (1989) *Trichosporon beigelii* pneumonia in a neutropenic patient. *European Journal of Clinical Microbiology & Infectious Diseases* **8**, 631–633.
37. Mathews MS and Prabhakar S (1995) Chronic meningitis caused by *Trichosporon beigelii* in India. *Mycoses* **38**, 125–126.
38. Reyes CV, Stanley MM and Rippon JW (1985) *Trichosporon beigelii* endocarditis as a complication of peritoneovenous shunt. *Human Pathology* **16**, 857–859.
39. Reinhart HH et al. (1988) Prosthetic valve endocarditis caused by *Trichosporon beigelii*. *The American Journal of Medicine* **84**, 355–358.
40. Tashiro T et al. (1995) *Trichosporon beigelii* pneumonia in patients with hematologic malignancies. *Chest* **108**, 190–195.
41. Hajjeh RA and Blumberg HM (1995) Bloodstream infection due to *Trichosporon beigelii* in a burn patient: case report and review of therapy. *Clinical Infectious Diseases* **20**, 913–916.
42. Walsh TJ et al. (2004) Infections due to emerging and uncommon medically important fungal pathogens. *Clinical Microbiology and Infection* **10**, 48–66.
43. Skiada A, Pavleas I and Drogari-Apiranthitou M (2017) Rare fungal infectious agents: a lurking enemy. *F1000Research* **6**, 1917.
44. Walsh TJ et al. (1992) Experimental *Trichosporon* infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. *The Journal of Infectious Diseases* **166**, 121–133.
45. Ogata K et al. (1990) Two cases of disseminated *Trichosporon beigelii* infection treated with combination antifungal therapy. *Cancer* **65**, 2793–2795.
46. Paphitou NI et al. (2002) In vitro antifungal susceptibilities of *Trichosporon* species. *Antimicrobial Agents and Chemotherapy* **46**, 1144–1146.
47. Takamura S et al. (1999) Disseminated Trichosporonosis with *Trichosporon asahii*. *European Journal of Dermatology* **9**, 577–579.
48. Toriumi Y et al. (2002) Antifungal pharmacodynamic characteristics of amphotericin B against *Trichosporon asahii*, using time-kill methodology. *Medical Microbiology and Immunology* **46**, 89–93.
49. Arendrup MC et al. (2014) ESCMID And ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. *Clinical Microbiology and Infection* **20**, 76–98.
50. Makinodan K et al. (2005) A familial case of summer-type hypersensitivity pneumonitis possibly associated with bird breeder's lung diagnosed by bronchoalveolar lavage fluid. *Nihon Kokyuki Gakkai Zasshi* **43**, 693–699.
51. Vashishtha VM, Mittal A and Garg A (2012) A fatal outbreak of *Trichosporon asahii* sepsis in a neonatal intensive care unit. *Indian Pediatrics* **49**, 745–747.
52. Miura Y et al. (2007) Breakthrough infection of *Trichosporon asahii* in a patient with chronic lymphocytic leukemia. *International Journal of Hematology* **85**, 177–178.
53. Pfaller MA and Diekema DJ (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond *Candida albicans* and *Aspergillus fumigatus*. *Journal of Clinical Microbiology* **42**, 4419–4431.
54. Rodriguez-Tudela JL et al. (2005) Susceptibility patterns and molecular identification of *Trichosporon* species. *Antimicrobial Agents and Chemotherapy* **49**, 4026–4034.
55. Rodriguez-Tudela JL et al. (2007) Genotype distribution of clinical isolates of *Trichosporon asahii* based on sequencing of intergenic spacer 1. *Diagnostic Microbiology and Infectious Disease* **58**, 435–440.
56. Guo LN et al. (2019) Invasive infections due to *Trichosporon*: species distribution, genotyping, and antifungal susceptibilities from a multicenter study in China. *Journal of Clinical Microbiology* **57**, e01505–e01518.
57. Girmenia C et al. (2005) Invasive infections caused by *Trichosporon* species and *Geotrichum capitatum* in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. *Journal of Clinical Microbiology* **43**, 1818–1828.
58. Liao Y et al. (2015) Epidemiology and outcome of *Trichosporon* fungemia: a review of 185 reported cases from 1975 to 2014. *Open Forum Infectious Diseases* **2**, ofv141.
59. Guo LN et al. (2011) Three-locus identification, genotyping, and antifungal susceptibilities of medically important *Trichosporon* species from China. *Journal of Clinical Microbiology* **49**, 3805–3811.
60. Ruan SY, Chien JY and Hsueh PR (2009) Invasive trichosporonosis caused by *Trichosporon asahii* and other unusual *Trichosporon* species at a medical center in Taiwan. *Clinical Infectious Diseases* **49**, e11–e17.
61. Kontoyiannis DP et al. (2004) Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. *Scandinavian Journal of Infectious Diseases* **36**, 564–569.
62. Cornely OA et al. (2019) Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European confederation of medical mycology. *Mycoses* **62**, 716–729.
63. Suzuki K et al. (2010) Fatal *Trichosporon* fungemia in patients with hematologic malignancies. *European Journal of Haematology* **84**, 441–447.
64. Krcmery V, Krupova I and Denning DW (1999) Invasive yeast infections other than *Candida* spp. in acute leukaemia. *Journal of Hospital Infection* **41**, 181–194.